Barinthus Biotherapeutics plc (BRNS)
Official siteHEALTHCARE • BIOTECHNOLOGY • PINK
Market Cap: $30.23M
Last updated: Nov 13, 2026 at 4:00 PM ET
Barinthus Biotherapeutics plc (BRNS) Stock Forecast
Analysts expect Barinthus Biotherapeutics (BRNS) to earn -$0.92 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.14.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.92
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.14
- EPS consensus
- Next report
- Mar 11, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.92 | -$0.93 to -$0.90 | 2 |
| Dec 31, 2027 | -$1.14 | -$1.20 to -$1.07 | 2 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.27 | N/A | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.15.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.92 | -$0.90 | -$1.15 | -$1.15 | -$1.15 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.14 | -$1.20 | -$1.15 | -$1.15 | -$1.15 | N/A |
Frequently Asked Questions About BRNS
What is the BRNS stock forecast?
Consensus analyst estimates put Barinthus Biotherapeutics's EPS at -$0.92 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from BRNS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.92, with estimates from -$0.93 to -$0.90 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.14, with estimates from -$1.20 to -$1.07 from 2 analysts.
How many analysts cover BRNS?
2 analysts estimate EPS for Barinthus Biotherapeutics for the fiscal year ending Dec 31, 2026.
BRNS pages: Overview, Earnings, Forecast, Financials, Competitors